GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Melanoma.

Adding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone. The addition of relatlimab ...

BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and ...

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...

Adding relatlimab to nivolumab and chemotherapy improved efficacy but did not increase safety concerns in advanced-stage lung cancer. The addition of relatlimab to nivolumab (Opdivo)—a combination ...

a fixed-dose combination of LAG-3 drug relatlimab with PD-1 inhibitor nivolumab, sold on its own as Opdivo. So far, that is only approved to treat melanoma but has grown quickly to reach $627 ...

LAG-3 drugs from arch-rivals Bristol-Myers Squibb ... with results showing a single infusion of its LAG-3 blocker relatlimab and its Opdivo immunotherapy improved progression-free survival in ...

But with too few staff and inadequate gear, they’re no match for the most dangerous threat now lurking in the national parks, violent drug cartels.